2 ). We calculated melphalan doses using ideal body weight (IBW), using adjusted IBW (ABW) for patients weighing .120% of IBW. We measured body composition using dual x-ray absorptiometry (DEXA), renal function with both iohexol clearance (Cl iohexol ) and the Cockroft-Gault formula (CrCl CG ), and plasma melphalan concentrations using HPLC/tandem mass spectrometry. We used non-compartmental analysis to estimate melphalan clearance (Cl MEL ) and area under the curve (AUC MEL ) and linear regression modeling to identify factors associated with melphalan pharmacokinetics. Results: Patients' mean BSA using actual weight was 1.93 m 2 (range 1.44-2.48). By DEXA scan, the mean lean body weight was 53.3 kg (SD 11.0) and mean fat percentage 31% (SD 9.5%). Mean iohexol clearance was 109 mL/min (range 28-163). AUC MEL varied significantly, with a range of 7.6-26.6 mg*h/L (mean 13.6, SD 3.8); Cl MEL was similarly variable (mean 27.9 mL/min, SD 8.1). In univariate analyses, Cl MEL was inversely related to age and directly related to weight, BSA, lean body weight, bone mineral content, Cl iohexol , CrCl CG , and MEL dose. Cl MEL was not associated with body fat percentage, body fat weight, or body lean percentage, or with other measurements, such as hemoglobin, albumin, immunoglobulins, or M-spike. The strongest correlation with Cl MEL was for CrCl CG , and multivariable models showed no improved prediction of Cl MEL with the addition of other factors to CrCl CG . The best model for predicting AUC MEL was dose/CrCl CG (see table) . These models consistently under-predicted AUC MEL (mean prediction error -3.3% to -2.6%). Plerixafor is a novel agent that enhances the mobilization of peripheral blood stem cells (PBSCs) in lymphoma and multiple myeloma (MM) patients whose cells mobilize poorly. Due to the substantial cost associated with its use, a cost utility analysis was performed to evaluate the economics of salvage Plerixafor in MM patients who failed previous mobilization. Methods: A decision model was developed to analyze the cost utility for two salvage regimens: Plerixafor + GCSF (PG) versus Cyclophosphamide + GCSF (CG). The model assumes that patients undergo mobilization with one of the regimens, followed by apheresis and subsequent autologous transplant if CD34+ cell count is $ 2 x 10 6 cells/kg, or Bortezomib plus Dexamethasone if insufficient CD34+ cells are collected. Patients included in the model will eventually progress and die from their disease. A structured literature review was performed to collect data on the successful mobilization rate, life year gained and quality of life associated with the modeled options. The analysis was from the perspective of Jordanian Ministry of Health; the costs were based on its list prices and included the costs of medications, apheresis, autologous transplant and adverse effects management. The willingness to pay threshold was $30,000 per quality adjusted life year (QALY). Incremental cost effectiveness ratio (ICER) was calculated by dividing the incremental average cost by the incremental QALY gained. One-way sensitivity analysis was performed to explore the impact of the uncertainty in efficacy data on the results. Results: The model showed that PG was associated with higher probability of achieving successful re-mobilization and subsequent transplant. The average total costs associated with CG and PG were $41,500 and $58,400 respectively. The estimated ICER was $52,813/QALY. (Table 1 ) The sensitivity analysis revealed that the ICERs ranged from $86,500 to $40,488 per QALY gained when the probability of PG success ranged from 60% to 95%. Conclusion: This analysis showed that the use of Plerixafor plus GCSF as salvage mobilization regimen in MM patients was not cost effective compared to Cyclophosphamide plus GCSF from the perspective of our health care system. To our knowledge, this is the first study to describe a cost utility analysis of Plerixafor use in this indication. 
